[1] 新型冠状病毒肺炎诊疗方案(试行第五版 修正版)[J]. 中国中西医结合杂志, 2020, 40(2): 136-138.
[2] HUANG K, ZHANG P, ZHANG Z H, et al. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms[J]. Pharmacol Ther,2021,225:107843. doi:  10.1016/j.pharmthera.2021.107843
[3] 徐宇琴, 陈燕, 傅真杰, 等. 基于网络药理学探究连花清瘟胶囊治疗新冠肺炎的作用机制[J]. 浙江中医药大学学报, 2021, 45(10):1154-1161,1168.
[4] 雷卓异, 范晓茜. 基于网络药理学和分子对接探讨预防肺疾一号方预防新型冠状病毒肺炎(COVID-19)的作用机制[J]. 世界科学技术-中医药现代化, 2021, 23(10):3541-3550.
[5] 杨嫄, 吴波, 陶国水, 等. 化湿败毒方治疗新型冠状病毒肺炎的网络药理学探究[J]. 山东中医药大学学报, 2022, 46(2):218-226.
[6] XU H Y, ZHANG Y Q, WANG P, et al. A comprehensive review of integrative pharmacology-based investigation: a paradigm shift in traditional Chinese medicine[J]. Acta Pharm Sin B,2021,11(6):1379-1399. doi:  10.1016/j.apsb.2021.03.024
[7] 陈凯欣, 尹力为, 李滋平. 基于数据挖掘的各省新型冠状病毒肺炎中医药治疗方案用药规律研究[J]. 辽宁中医药大学学报, 2021, 23(5):100-107.
[8] 张佳, 李晓东. 基于数据挖掘的各地区新冠肺炎恢复期中医药组方用药规律研究[J]. 湖北中医药大学学报, 2020, 22(6):117-121. doi:  10.3969/j.issn.1008-987x.2020.06.33
[9] 闫玉凤, 董平. 上海市新型冠状病毒肺炎恢复期患者中药饮片用药特点分析[J]. 江苏中医药, 2020, 52(4):80-83.
[10] 邵灿灿, 王豪杰, 孟鹏飞, 等. 新型冠状病毒肺炎的中医认识及治疗现状[J]. 中医学报, 2020, 35(4):704-708.
[11] MAO K M, TAN Q, MA Y L, et al. Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 months of recovery[J]. Cell Death Dis,2021,12(6):541. doi:  10.1038/s41419-021-03816-3
[12] 赵静, 刘剑锋, 王燕平, 等. 中药复方分期治疗新冠肺炎的网络药理学分析[J]. 世界科学技术-中医药现代化, 2020, 22(2):278-288.
[13] 陶嘉磊, 单进军, 袁斌. MS-DAIL联合MS-FINDER鉴定中药黄酮类化合物[J]. 世界科学技术-中医药现代化, 2021, 23(10):3704-3711.
[14] 王依明, 王秋红. 半夏的化学成分、药理作用及毒性研究进展[J]. 中国药房, 2020, 31(21):2676-2682. doi:  10.6039/j.issn.1001-0408.2020.21.20
[15] 谢琦, 程雪梅, 胡芳弟, 等. 党参化学成分、药理作用及质量控制研究进展[J]. 上海中医药杂志, 2020, 54(8):94-104.
[16] GAO S M, LIU J S, WANG M, et al. Exploring on the bioactive markers of Codonopsis radix by correlation analysis between chemical constituents and pharmacological effects[J]. J Ethnopharmacol,2019,236:31-41. doi:  10.1016/j.jep.2019.02.032
[17] 邓桃妹, 彭代银, 俞年军, 等. 茯苓化学成分和药理作用研究进展及质量标志物的预测分析[J]. 中草药, 2020, 51(10):2703-2717. doi:  10.7501/j.issn.0253-2670.2020.10.013
[18] RÍOS J L. Chemical constituents and pharmacological properties of Poria Cocos[J]. Planta Med,2011,77(7):681-691. doi:  10.1055/s-0030-1270823
[19] SU H F, SHAKER S, KUANG Y, et al. Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix)[J]. Med Res Rev,2021,41(4):1999-2038. doi:  10.1002/med.21785
[20] 戴瑜婷, 张雪燕, 王艺璇, 等. 黄芪的现代研究进展及其质量标志物的预测分析[J]. 中国中药杂志, 2022, 47(7):1754-1764.
[21] 凡杭, 聂安政, 包莉, 等. 藿香化学成分与药理作用研究进展[J]. 中国野生植物资源, 2021, 40(11):45-53. doi:  10.3969/j.issn.1006-9690.2021.11.009
[22] 徐方方, 陈伟英, 蔡婉娜, 等. 砂仁的化学成分及质量控制方法的研究进展[J]. 世界中医药, 2020, 15(24):3881-3886,3894. doi:  10.3969/j.issn.1673-7202.2020.24.031
[23] 黄斌, 胡燕珍, 李雪, 等. 基于UPLC-Q-TOF-MS技术分析乌蕨中的化学成分[J]. 实用中西医结合临床, 2021, 21(9):155-159.
[24] 秦伟瀚, 冉继春, 叶良红, 等. UPLC-Q/TOF法同时定性定量分析滇芹药材中主要化学成分[J]. 中草药, 2018, 49(15):3576-3582. doi:  10.7501/j.issn.0253-2670.2018.15.016
[25] 吴茵, 白万军, 魏欣. 基于UPLC-Q-TOF-MS技术分析木蝴蝶中化学成分[J]. 中国实验方剂学杂志, 2019, 25(2):196-200.
[26] BAHUN M H, JUKI\U0107 M, OBLAK D, et al. Inhibition of the SARS-CoV-2 3CL pro main protease by plant polyphenols[J]. Food Chem, 2022, 373(Pt B): 131594.
[27] HAQ M M, CHOWDHURY M A R, TAYARA H, et al. A report on multi-target anti-inflammatory properties of phytoconstituents from Monochoria hastata (Family: Pontederiaceae)[J]. Molecules,2021,26(23):7397. doi:  10.3390/molecules26237397
[28] THAKARE V N, PATIL R R, SURALKAR A A, et al. Protocatechuic acid attenuate depressive-like behavior in olfactory bulbectomized rat model: behavioral and neurobiochemical investigations[J]. Metab Brain Dis,2019,34(3):775-787. doi:  10.1007/s11011-019-00401-8
[29] WANG X H, DAI C, WANG J, et al. Therapeutic effect of neohesperidin on TNF-α-stimulated human rheumatoid arthritis fibroblast-like synoviocytes[J]. Chin J Nat Med,2021,19(10):741-749.
[30] AL-SANEA M M, ABELYAN N, ABDELGAWAD M A, et al. Strawberry and ginger silver nanoparticles as potential inhibitors for SARS-CoV-2 assisted by in silico modeling and metabolic profiling[J]. Antibiotics (Basel),2021,10(7):824. doi:  10.3390/antibiotics10070824
[31] YANG R C, LIU H, BAI C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): in silico and experimental study[J]. Pharmacol Res,2020,157:104820. doi:  10.1016/j.phrs.2020.104820
[32] TAN Y Q, CHEN H W, LI J. Astragaloside IV: an effective drug for the treatment of cardiovascular diseases[J]. Drug Des Devel Ther,2020,14:3731-3746. doi:  10.2147/DDDT.S272355
[33] JIANG B, YANG Y J, DANG W Z, et al. Astragaloside IV reverses simvastatin-induced skeletal muscle injury by activating the AMPK-PGC-1α signalling pathway[J]. Phytother Res,2020,34(5):1175-1184. doi:  10.1002/ptr.6593